

THE PHENOPATH CONFERENCE

A Conference for the Seattle Pathology Community
Thursday, May 16, 2019

Dr. Jeffrey S. Ross

*Medical Director
Foundation Medicine
150 Second Street
Cambridge, MA 02141*



6:00-7:00pm:

Please join us for a light catered dinner and meet your Seattle area colleagues.

7:00-8:00pm Lecture and Q&A:

Biomarkers of Immuno-Oncology Drug Response.



**FOUNDATION
MEDICINE**

*Parking tokens will be provided.

See Dr. Ross's biosketch on our web page. Dr. Ross will also be giving a lecture on **The Interface Between Surgical and Molecular Pathology in the Era of Genomic Medicine** at 12 Noon, the same day, to which you are also invited.

PhenoPath
LABORATORIES
Diagnoses you can count on™

551 N. 34th St, Suite 100, Seattle, WA 98103
(206) 374-9000 | www.phenopath.com | lab@phenopath.com

Biosketch:

Dr. Jeffrey S. Ross

Jeffrey S. Ross, M.D. is a graduate of Oberlin College, Oberlin, Ohio and The State University of New York at Buffalo School of Medicine in Buffalo, New York. He trained in Pathology at the Massachusetts General Hospital in Boston, Massachusetts. From 1977 until 1989 he was Professor and Assistant Dean at University of Massachusetts Medical School and research Assistant Professor at Harvard Medical School and the Massachusetts General Hospital. Dr. Ross was the Cyrus Strong Merrill Professor and Chairman of the Department of Pathology and Laboratory Medicine at the Albany Medical College in Albany, New York from 1989 to 2017. In 2017, Dr. became the Jones-Rohner Endowed Professor of Pathology, Oncology and Urology at the Upstate Medical University in Syracuse, NY. In 2009, Dr. Ross became the Founding Strategic Advisor and the Medical Director for Foundation Medicine, Inc. in Cambridge, MA.

Dr. Ross has received numerous academic awards, four patents in molecular diagnostics and is the author of more than 900 peer-reviewed scientific articles and abstracts, 4 textbooks and numerous book chapters in the fields of pathology, molecular diagnostics, oncology and translational cancer research.